Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703968 | 0.96 | DPP4 (0.46) | DPP4DPP8DPP9TP53CYP3A4 | |
| SCHEMBL2703047 | 0.89 | DPP4 (0.44) | DPP4DPP8DPP9CYP3A4 | |
| SCHEMBL2705021 | 0.88 | DPP4 (0.41) | DPP4DPP8DPP9MDM2TP53 | |
| SCHEMBL2705023 | 0.88 | DPP4 (0.41) | DPP4DPP8DPP9MDM2TP53 | |
| SCHEMBL4020045 | 0.86 | DPP4 (0.45) | DPP4DPP8DPP9CYP3A4 | |
| SCHEMBL4408181 | 0.84 | DPP4 (0.41) | DPP4DPP8DPP9CYP3A4 | |
| SCHEMBL2704020 | 0.84 | DPP4 (0.43) | DPP4DPP8DPP9MDM2TP53 | |
| SCHEMBL4405098 | 0.84 | DPP4 (0.51) | DPP4DPP8DPP9CYP3A4 | |
| Hydrochloric Acid SCHEMBL2703325 | 0.83 | DPP4 (0.50) | DPP4DPP8DPP9CYP3A4 | |
| SCHEMBL2701634 | 0.83 | GPR119 (0.39) | DPP4DPP8DPP9MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888589-B1 | PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 7/4885DPP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.